Nitroaspirin (NCX 4016) 是一氧化氮 (NO) 供体和阿司匹林的硝基衍生物，Aspirin 与 Nitroaspirin 联合以抑制环加氧酶。Nitroaspirin (NCX 4016) 具有抗血栓形成和抗血小板特性，并作为 COX-1 的直接和不可逆抑制剂。Nitroaspirin (NCX 4016) 通过下调 EGFR/PI3K/STAT3 信号传导和调节 Bcl-2 家族蛋白，在顺铂耐药人卵巢癌细胞中引起细胞周期停滞和凋亡。
CAS：175033-36-0
分子式：C16H13NO7
分子量：331.28
纯度：98%
存储：Store at -20°C

Background:

Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin (NCX 4016) has antithrombotic and anti-platelet properties and acts as a direct and irreversible inhibitor of COX-1. Nitroaspirin (NCX 4016) causes significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins[1][2][3][4]. COX-1

[1]. Selvendiran K, et al. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 2008 Jan 1;7(1):81-8. [2]. Bertuglia S, et al. Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheekpouch microcirculation. Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G437-43. [3]. Corazzi T, et al. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. [4]. Selvendiran K, et al. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 2008 Jan 1;7(1):81-8.